{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:29:41Z","timestamp":1791188981618,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncpneph0476","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T09:49:15Z","timestamp":1177494555000},"page":"287-293","source":"Crossref","is-referenced-by-count":74,"title":["Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma"],"prefix":"10.1038","volume":"3","author":[{"given":"Daniel","family":"Roncone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Satoskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Nadasdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Paul","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneph0476_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.407.11.1","volume":"11","author":"H Watanabe","year":"2005","unstructured":"Watanabe H et al. (2005) Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB\/W F1 murine systemic lupus erythematosus model. Clin Can Res 11: 407\u2013409","journal-title":"Clin Can Res"},{"key":"BFncpneph0476_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","volume":"23","author":"BI Rini","year":"2005","unstructured":"Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Onc 23: 1028\u20131043","journal-title":"J Clin Onc"},{"issue":"Suppl 3","key":"BFncpneph0476_CR3","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl 3): S25\u2013S33","journal-title":"Oncology"},{"key":"BFncpneph0476_CR4","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","volume":"10","author":"BI Rini","year":"2004","unstructured":"Rini BI et al. (2004) Cancer and leukemia group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Can Res 10: 2584\u20132586","journal-title":"Clin Can Res"},{"key":"BFncpneph0476_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 349: 427\u2013434","journal-title":"N Eng J Med"},{"issue":"Suppl 1","key":"BFncpneph0476_CR6","first-page":"S1","volume":"4","author":"LM Ellis","year":"2006","unstructured":"Ellis LM et al. (2006) Overview of anti-VEGF therapy and angiogenesis: angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol 4 (Suppl 1): S1\u2013S12","journal-title":"Clin Adv Hematol Oncol"},{"key":"BFncpneph0476_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK et al. (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24\u201340","journal-title":"Nat Clin Pract Oncol"},{"key":"BFncpneph0476_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF et al. (2004) The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 65: 2003\u20132017","journal-title":"Kidney Int"},{"key":"BFncpneph0476_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/ndt\/16.4.846","volume":"16","author":"C Badid","year":"2001","unstructured":"Badid C et al. (2001) Renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 16: 846\u2013848","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0476_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","volume":"12","author":"AS De Vriese","year":"2001","unstructured":"De Vriese AS et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993\u20131000","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0476_CR11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/ndt\/gfh336","volume":"19","author":"A Gordon","year":"2004","unstructured":"Gordon A et al. (2004) Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Nephrol Dial Transplant 19: 2155\u20132157","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0476_CR12","doi-asserted-by":"publisher","first-page":"12605","DOI":"10.1074\/jbc.C300012200","volume":"278","author":"H Sugimoto","year":"2003","unstructured":"Sugimoto H et al. (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605\u201312608","journal-title":"J Biol Chem"},{"key":"BFncpneph0476_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707\u2013716","journal-title":"J Clin Invest"},{"key":"BFncpneph0476_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard SE et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649\u2013658","journal-title":"J Clin Invest"},{"key":"BFncpneph0476_CR15","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/j.1523-1755.2005.00316.x","volume":"67","author":"SA Karumanchi","year":"2005","unstructured":"Karumanchi SA et al. (2005) Preeclampsia: a renal perspective. Kidney Int 67: 2101\u20132113","journal-title":"Kidney Int"},{"key":"BFncpneph0476_CR16","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1097\/01.ASN.0000141038.28733.F2","volume":"15","author":"A Shimizu","year":"2004","unstructured":"Shimizu A et al. (2004) Vascular endothelial growth factor-165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 15: 2655\u20132665","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0476_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0002-9440(10)61731-2","volume":"159","author":"Y Masuda","year":"2001","unstructured":"Masuda Y et al. (2001) Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159: 599\u2013608","journal-title":"Am J Pathol"},{"key":"BFncpneph0476_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1053\/ajkd.2002.32773","volume":"39","author":"SI Ha","year":"2002","unstructured":"Ha SI et al. (2002) Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 39: 1001\u20131010","journal-title":"Am J Kidney Dis"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0476","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:17:35Z","timestamp":1684441055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncpneph0476"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0476","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}